Patents by Inventor Yasuhiko Koezuka
Yasuhiko Koezuka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101711Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.Type: ApplicationFiled: November 21, 2023Publication date: March 28, 2024Applicants: HUBIT GENOMIX, INC., NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENTInventors: Hirohisa SAITO, Kenji MATSUMOTO, Hideaki MORITA, Go ICHIEN, Yasuhiko KOEZUKA, Kimishige ISHIZAKA
-
Patent number: 11827719Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.Type: GrantFiled: April 6, 2020Date of Patent: November 28, 2023Assignees: HOBIT GENOMIX, INC., NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENTInventors: Hirohisa Saito, Kenji Matsumoto, Hideaki Morita, Go Ichien, Yasuhiko Koezuka, Kimishige Ishizaka
-
Publication number: 20200231705Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereofType: ApplicationFiled: April 6, 2020Publication date: July 23, 2020Inventors: Hirohisa Saito, Kenji Matsumoto, Hideaki Morita, Go Ichien, Yasuhiko Koezuka, Kimishige Ishizaka
-
Patent number: 7488491Abstract: The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes glycosylceramide, preferably ?-galactosylceramide (?-GalCer). According to the present invention, the use of glycosylceramide as an adjuvant is attributed at least in part to the enhancement and/or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses. The methods and compositions of the present invention can be useful for prophylaxis and treatment of various infectious and neoplastic diseases.Type: GrantFiled: July 25, 2002Date of Patent: February 10, 2009Assignee: New York UniversityInventors: Moriya Tsuji, Gloria Gonzalez-Aseguinolaza, Yasuhiko Koezuka
-
Patent number: 7029671Abstract: The invention relates to a method for activating human-derived antigen-presenting cells by in vitro cultivation with at least one of the glycoside compounds represented by formula (A) or salts thereof [preferred example: (2S,3S,4R)-1-(?-D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecanediol], and to human antigen-presenting cells activated by the method. The invention also relates to a method for treatment of cancer and infectious diseases including AIDS with the activated human antigen-presenting cells, and to a use of the activated human antigen-presenting cells in the preparation of medicines for treating such diseases. The invention can provide a satisfactory therapeutic effect on cancer and infectious diseases including AIDS without the need to pulse the human antigen-presenting cells with tumor antigens.Type: GrantFiled: November 27, 2000Date of Patent: April 18, 2006Assignee: Kirin Brewery Company, LimitedInventors: Yasuhiko Koezuka, Yasunori Yamaguchi, Kazuhiro Motoki
-
Publication number: 20060073122Abstract: The invention relates to a method for activating human-derived antigen-presenting cells by in vitro cultivation with at least one of the glycoside compounds represented by formula (A) or salts thereof [preferred example: (2S,3S,4R)-1-(?-D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecanediol], and to human antigen-presenting cells activated by the method. The invention also relates to a method for treatment of cancer and infectious diseases including AIDS with the activated human antigen-presenting cells, and to a use of the activated human antigen-presenting cells in the preparation of medicines for treating such diseases. The invention can provide a satisfactory therapeutic effect on cancer and infectious diseases including AIDS without the need to pulse the human antigen-presenting cells with tumor antigens.Type: ApplicationFiled: October 6, 2005Publication date: April 6, 2006Inventors: Yasuhiko Koezuka, Yasunori Yamaguchi, Kazuhiro Motoki
-
Patent number: 6747010Abstract: An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.Type: GrantFiled: January 2, 2003Date of Patent: June 8, 2004Assignee: Kirin Beer Kabushiki KaishaInventors: Masaru Taniguchi, Tetsu Kawano, Yasuhiko Koezuka
-
Publication number: 20030157135Abstract: The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes glycosylceramide, preferably &agr;-galactosylceramide (&agr;-GalCer). According to the present invention, the use of glycosylceramide as an adjuvant is attributed at least in part to the enhancement and/or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses. The methods and compositions of the present invention can be useful for prophylaxis and treatment of various infectious and neoplastic diseases.Type: ApplicationFiled: July 25, 2002Publication date: August 21, 2003Applicant: NEW YORK UNIVERSITYInventors: Moriya Tsuji, Gloria Gonzalez-Aseguinolaza, Yasuhiko Koezuka
-
Publication number: 20030139351Abstract: An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.Type: ApplicationFiled: January 2, 2003Publication date: July 24, 2003Applicant: KIRIN BEER KABUSHIKI KAISHAInventors: Masaru Taniguchi, Tetsu Kawano, Yasuhiko Koezuka
-
Patent number: 6531453Abstract: An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.Type: GrantFiled: October 12, 1999Date of Patent: March 11, 2003Assignee: Kirin Beera Kabushiki KaishaInventors: Masaru Taniguchi, Tetsu Kawano, Yasuhiko Koezuka
-
Patent number: 6071884Abstract: The present invention relates to a method for the treatment of thrombocytopenia wherein an effective amount of a compound represented by the formula (A) is administered to a patient: wherein R.sub.2 represents H or OH, X is an integer of 0-26 or R represents --(CH.sub.2).sub.7 CH.dbd.CH(CH.sub.2).sub.7 CH.sub.3, and R.sub.1 is a substituent defined by the following (a) to (d):(a) --CH.sub.2 (CH.sub.2).sub.y CH.sub.3,(b) --CH(OH)(CH.sub.2).sub.y CH.sub.3,(c) --CH(OH)(CH.sub.2).sub.y CH(CH.sub.3).sub.2, or(d) --CH.dbd.(CH)(CH.sub.2).sub.y CH.sub.3wherein Y is an integer of 5-17.Type: GrantFiled: October 28, 1998Date of Patent: June 6, 2000Assignee: Kirin Beer Kabushiki KaishaInventors: Yasuhiko Koezuka, Koji Kabaya, Kazuhiro Motoki
-
Patent number: 6017892Abstract: The present invention relates to a pharmaceutical composition (a marrow cell proliferation accelerator, a radioprotective agent, a therapeutic agent for thrombocytopenia) comprising a compound represented by the following formula (A), and to a therapeutic or prophylactic method (a method for accelerating marrow cell proliferation, a method for protecting human against radiation damage, a method for the treatment of thrombocytopenia) characterized in that an effective amount of a compound represented by the following formula (A) is administered to human: ##STR1## wherein R represents ##STR2## (wherein R.sub.2 represents H or OH, X is an integer of 0-26) or --(CH.sub.2).sub.7 CH.dbd.CH(CH.sub.2).sub.7 CH.sub.3, and R.sub.1 is one of the substituents defined by the following (a) to (d):--CH.sub.2 (CH.sub.2).sub.Y CH.sub.3, (a)--CH(OH)(CH.sub.2).sub.Y CH.sub.3, (b)--CH(OH)(CH.sub.2).sub.Y CH(CH.sub.3).sub.2, (c)and--CH.dbd.CH(CH.sub.2).sub.Y CH.sub.3 (d)(wherein Y is an integer of 5-17).Type: GrantFiled: June 23, 1997Date of Patent: January 25, 2000Assignee: Kiran Beer Kabushiki KaishaInventors: Yasuhiko Koezuka, Koji Kabaya, Kazuhiro Motoki
-
Patent number: 5936076Abstract: The present invention relates to the novel .alpha.-galactosylceramide represented by the formula (A): ##STR1## wherein R represents ##STR2## where R.sub.2 represents H or OH and X denotes an integer of 0-26, or R represents --(CH.sub.2).sub.7 CH.dbd.CH(CH.sub.2).sub.7 CH.sub.3 and R.sub.1 represents any one of the substituents defined by the following (a)-(e):(a) --CH.sub.2 (CH.sub.2).sub.Y CH.sub.3,(b) --CH(OH)(CH.sub.2).sub.Y CH.sub.3,(c) --CH(OH)(CH.sub.2).sub.Y CH(CH.sub.3).sub.2,(d) --CH.dbd.CH(CH.sub.2).sub.Y CH.sub.3, and(e) --CH(OH)(CH.sub.2).sub.Y CH(CH.sub.3)CH.sub.2 CH.sub.3,wherein Y denotes an integer of 5-17.The present invention also relates to an anti-tumor agent and an immunostimulator comprising one or more of the aforementioned compounds as effective ingredients.Type: GrantFiled: May 25, 1995Date of Patent: August 10, 1999Assignee: Kirin Beer Kabushiki KaishaInventors: Tatsuo Higa, Koji Akimoto, Yasuhiko Koezuka, Teruyuki Sakai, Masahiro Morita, Takenori Natori
-
Patent number: 5849716Abstract: The present invention relates to a sphingoglycolipid represented by the following formula (I) which is effective at a small dose and has an anti-tumor activity and an immunostimulating effect with few side-effects: ##STR1## wherein X denotes an integer from 10 to 24, Y denotes an integer from 9 to 13,R.sub.1 represents a hexosyl, pentosyl, deoxyhexosyl, aminohexosyl, N-acetylaminohexosyl or a halide thereof or a sialic acid,R.sub.2 represents H or a group OR.sub.2 ', wherein R.sub.2 ' represents H or a galactosyl or glucosyl group,R.sub.3 represents H or a group OR.sub.3 ', wherein R.sub.3 ' represents H or a galactosyl or glucosyl group,R.sub.4 represents a galactosyl group or H,R.sub.5 represents a methyl or isopropyl group,R.sub.6 and R.sub.7 respectively represents H or form a double bond between the two carbon atoms to which R.sub.6 and R.sub.7 are attached,except for the case where R.sub.1 represents .alpha.-galactosyl and R.sub.4 represents H.Type: GrantFiled: April 21, 1995Date of Patent: December 15, 1998Assignee: Kirin Beer Kabushiki KaishaInventors: Koji Akimoto, Yasuhiko Koezuka
-
Patent number: 5780441Abstract: The present invention relates to a sphingoglycolipid represented by the formula (I): ##STR1## wherein R.sub.1, R.sub.2 and R.sub.5 represent H or a specific monosaccharide; R.sub.3 and R.sub.6 represent H or OH, respectively;R.sub.4 represents H, OH or a specific monosaccharide;X denotes an integer from 19 to 23;R.sub.7 represents any one of the following groups (a)-(g):(a) --(CH.sub.2).sub.11 --CH.sub.3,(b) --(CH.sub.2).sub.12 --CH.sub.3,(c) --(CH.sub.2).sub.13 --CH.sub.3,(d) --(CH.sub.2).sub.9 --CH(CH.sub.3).sub.2,(e) --(CH.sub.2).sub.10 --CH(CH.sub.3).sub.2,(f) --(CH.sub.2).sub.11 --CH(CH.sub.3).sub.2,(g) --(CH.sub.2).sub.11 --CH(CH.sub.3)--C.sub.2 H.sub.5.Type: GrantFiled: May 7, 1996Date of Patent: July 14, 1998Assignee: Kirin Beer Kabushiki KaishaInventors: Tatsuo Higa, Takenori Natori, Yasuhiko Koezuka, Kazuhiro Motoki
-
Patent number: 5767092Abstract: The present invention relates to a pharmaceutical composition (a marrow cell proliferation accelerator, a radioprotective agent, a therapeutic agent for thrombocytopenia) comprising a compound represented by the following formula (A), and to a therapeutic or prophylactic method (a method for accelerating marrow cell proliferation, a method for protecting human against radiation damage, a method for the treatment of thrombocytopenia) characterized in that an effective amount of a compound represented by the following formula (A) is administered to human: ##STR1## wherein R.sub.2 represents ##STR2## 26) or --(CH.sub.2).sub.7 CH=CH(CH.sub.2).sub.7 CH.sub.3, and R.sub.1, is one of the substituents defined by the following (a) to (d):(a) --CH.sub.2 (CH.sub.2).sub.y CH.sub.3,(b) --CH(OH)(CH.sub.2).sub.y (CH.sub.3).sub.2, and(c) --CH(OH)(CH.sub.2).sub.y CH(CH.sub.3).sub.2, and(d) --CH=CH(CH.sub.2).sub.y CH.sub.3(wherein Y is an integer of 5-17).Type: GrantFiled: March 17, 1995Date of Patent: June 16, 1998Assignee: Kirin Beer Kabushiki KaishaInventors: Yasuhiko Koezuka, Koji Kabaya, Kazuhiro Motoki